• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press releases
  • Suppliers
  • Contact
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • About
    • Company
    • Management Team
    • Board of Directors
    • Collaborators
    • Contact
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel
    • ATA188
    • ATA2271/ATA3271
    • ATA3219
  • Patients
    • Mission to Serve Patients
    • Clinical Studies
    • Expanded Access
    • Request Information
    • PTLD Champions
    • Multiple Sclerosis
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Join Our Team
    • Life at Atara
    • Explore Career Opportunities
    • Tech Ops
    • Job Search
  • Medical Professionals
  • Suppliers
  • Press Releases
  • Contact
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mar 05, 2021 4:01pm EST

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

Mar 01, 2021 4:05pm EST

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

Feb 18, 2021 4:01pm EST

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-celĀ® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Feb 08, 2021 9:00am EST

Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Jan 19, 2021 4:14pm EST

Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference

Jan 10, 2021 4:06pm EST

Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Jan 06, 2021 8:30am EST

Atara Biotherapeutics Provides Regulatory Update for Tab-CelĀ® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Jan 04, 2021 7:30am EST

Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering

Dec 08, 2020 9:26pm EST

Atara Biotherapeutics Announces Proposed Offering of Common Stock

Dec 07, 2020 4:07pm EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...22
Next
  • Email Alerts
  • Contacts
  • RSS News Feed

Footer

  • LinkedIn linkedin
  • Twitter twitter
© 2021 Atara Biotherapeutics, Inc. All Rights Reserved
  • Privacy Policy
  • Sitemap

This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy


OK